Traws Therapeutics - מכפיל EV/Sales TRAW

Geopolitical supply risks from Asia and patent disputes are putting pressure on Traws Pharma, Inc. (TRAW), which is partially offset by the diversification of its antiviral portfolio. The GURU.Markets service calculates the EV-to-revenue multiple, where 0.00 expresses today's metric value, reflecting the current valuation. Growth prospects are driven by an active restructuring of the biopharmaceutical pipeline and the launch of new clinical trials.
TRAW (Traws Pharma, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Traws Pharma, Inc. (TRAW) is developing its antiviral portfolio, mitigating seasonal revenue risks through drug diversification. The current EV/Revenue multiple reflects the enterprise value of the business inclusive of net debt, allowing investors to assess the real price of each unit of sales without distortions from the financing structure. A decline in this multiple signals an asset revaluation amid tight monetary policy.